Safety and efficacy in patients with Inflammatory bowel disease (Crohn's disease and Ulcerative colitis) switched from Infliximab innovator to Infliximab biosimilar: a prospective, cohort, observational, multicenter study

Trial Profile

Safety and efficacy in patients with Inflammatory bowel disease (Crohn's disease and Ulcerative colitis) switched from Infliximab innovator to Infliximab biosimilar: a prospective, cohort, observational, multicenter study

Completed
Phase of Trial: Phase IV

Latest Information Update: 12 Dec 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease; Ulcerative colitis
  • Focus Adverse reactions; Therapeutic Use
  • Most Recent Events

    • 12 Dec 2017 New trial record
    • 05 Dec 2017 Results assessing safety and efficacy published in the Alimentary Pharmacology and Therapeutics.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top